

UofSC COP Annual Continuing Education Conference: Day 1 and Day 2

Saturday, February 1, 2020 AND Saturday, February 22, 2020 8:00 am to 4:05 pm

Location:

University of South Carolina College of Pharmacy Coker Life Sciences Building Room 215, 715 Sumter Street, Columbia, SC 29208

Target Audience: Pharmacists and Pharmacy Technicians

Topics & Faculty: See pages 2-3 for full program agenda and learning objectives!

Live Programming available on Saturday, February 1, 2020 (6 hours)



Overcoming Migraines:		
Novel Medications to Treat		
and Prevent Migraines		

Betsy Blake, PharmD, BCPS Clinical Associate Professor and Director of Interprofessional Education, UofSC COP; Co-Chair, Interprofessional Education for the Health Sciences, UofSC

New Approaches to Pain Management: Multimodal **Opioid-Free Analgesia**

Disturbances in the

Geriatric Population

Michaela Almgren, PharmD, MS Clinical Assistant Professor, UofSC COP

Dementia and Behavioral

The Value of Integrating Pharmacists into Primary Care

Karen McGee, PharmD, CDE, BCGP Clinical Associate Professor, UofSC COP; Clinical Pharmacist, Prisma Health SeniorCare PACE

Patricia H. Fabel, PharmD, BCPS Executive Director, Kennedy Pharmacy Innovation Center: Clinical Associate Professor, UofSC COP



Top 10 Infectious Diseases Topics of 2019

Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS Associate Professor and Director of Residency & Fellowship Training, UofSC COP; Infectious Diseases PGY2 & Clinical Fellowship Director, Prisma Health Richland

Live Programming available on Saturday, February 22, 2020 (6 hours)



Drugs of Abuse: A Focused Update on Abuse and Monitoring

Jordan Cooler, PharmD, BCPP Clinical Assistant Professor, UofSC COP; Psychiatric Pharmacist, UofSC Student Health Center

Hypertension: Classification, Management, Julie Sease, PharmD, FCCP and Monitoring of the Most Common Disease



Determining Decisions and Deciphering Dilemmas in Dyslipidemia with Updated American College of Cardiology/American Heart Association Cholesterol Guidelines

State



Beyond Diabetes: Benefits of SGLT2 Inhibitors and GLP-1 Agonists

Community Acquired Pneumonia Update



Management of Pit Viper and **Black Widow Envenomation**

Senior Associate Dean and Professor, UofSC COP

Cynthia Phillips, PharmD, CDE Clinical Associate Professor, UofSC COP; Clinical Pharmacist, Prisma Health Richland

Brie Dunn, PharmD Associate Dean for Outcomes Assessment & Accreditation and Clinical Associate Professor; UofSC COP

Hana Rac Winders, PharmD, BCIDP Lead Antimicrobial Stewardship Pharmacist, Antimicrobial Stewardship Collaborative of South Carolina (ASC-SC); Clinical Assistant Professor, UofSC COP

> Jill Michels, PharmD, DABAT Clinical Associate Professor, UofSC COP Managing Director, Palmetto Poison Center

Home Study Programming Available to All Registrants (1 hour)



Immunized People 2020: An Immunization Update

Registration:	Register online at <u>https://cop.sc.learningexpressce.com</u> Registration will remain open until Friday, January 24, 2020 at 8:00 am		
Note: Fees include continental breakfast and lunch		Pharmacists**	Pharmacy Technicians
	Single day, prior to January 6, 2020*	\$130	\$85
	Both days (2/1 and 2/22), prior to January 6, 2020*	\$230	\$140
	*All registration fees will increase by \$20 after January 6, 2020.		
	**PEEP Preceptors: Check your email for information from the PEEP Office on discounted registration!		
	Fees will appear as "Learning Express" on your credit card statement		
Cancellations:	UofSC COP reserves the right to cancel the entire program. In the event of a cancellation, each participant will be notified via email prior to the program and a full tuition refund will be made. All refunds should be requested in writing on or before January 17, 2020 and will be subject to a 7.5% administrative fee. No cancellation requests will be accepted after January 17, 2020.		
Accreditation:	The University of South Carolina College of Pharmacy is ac for Pharmacy Education as a provider of continuing pharma		editation Council
	This program has been accredited for 12.0 live contact hours (1.2 CEUs) and 1.0 home study contact (0.1 CEU) for pharmacists and pharmacy technicians. Five live hours on 2/1 and six live hours on 2, qualify as "drug therapy or patient management", with one live hour each day designed to combat th epidemic through pain management and "approved procedures for monitoring controlled substances home study hour serves as an immunization update for immunizing pharmacists and will qualify as " therapy or patient management".		
	Participants must sign in at the program and have attendance verified. Participants must complete online evaluations within 30 days to facilitate transmission to the CPE Monitor. Failure to provide correct and/or complete information may result in your activity not being reported to the CPE Monitor. ACPE requires that all credit be claimed and reported within 60 days after the live event or completion of the home study.		

Day 1: Full Program Agenda and Learning Objectives - Saturday, February 1

8:00 am-8:3	8:00 am-8:30 am: Registration/Check-In and Welcome (Light continental breakfast provided)			
8:30 am- 10:00 am	Overcoming Migraines: Novel Medications to Treat and Prevent Migraines Betsy Blake, PharmD, BCPS (1.5 hours, ACPE UAN 0062-0000-20-002-L01-P/T, application-based)			
A	 At the completion of this activity, the pharmacist will be able to: 1. Describe migraine headaches and the criteria for diagnosis 2. Discuss lifestyle modifications to decrease migraine episodes 3. Review the evidence for new and existing therapies to treat and prevent migraines 4. Demonstrate the appropriate administration of injectable migraine therapies 	 At the completion of this activity, the technician will be able to: 1. Describe migraine headaches 2. Discuss lifestyle modifications to decrease migraine episodes 3. Review medications to treat and prevent migraines 4. Demonstrate the appropriate administration of injectable migraine medications 		
):15 am: Break			
10:15 am-	New Approaches to Pain Management: Multimodal Opioid-Free Analgesia			
11:15 am	Michaela Almgren, PharmD, MS (1.0 hours, ACPE UAN 0062-0000-20-003-L01-P/T, knowledge-based)			
	 At the completion of this activity, the pharmacist will be able to: 1. Review the impact of the opioid epidemic in the U.S. and SC 2. Discuss the pathophysiology of pain 3. Describe different types of pain and current treatment protocols 4. Define preemptive, preventive and multimodal analgesia 5. Explain the use of multimodal analgesia as an alternative to opioids 	 At the completion of this activity, the technician will be able to: 1. Review the impact of the opioid epidemic in the U.S. and SC 2. Discuss the pathophysiology of pain 3. Describe different types of pain and current treatment protocols 4. Define preemptive, preventive and multimodal analgesia 5. Explain the use of multimodal analgesia as an alternative to opioids 		
11:15 am-		oances in the Geriatric Population		
12:15 pm	Karen McGee, PharmD, CDE, BCGP (1.0 hours, ACPE UAN 0062-0000-20-004-L01-P/T, application-based)			
	 At the completion of this activity, the pharmacist will be able to: Classify common types of dementia Review medications of choice for memory loss and agitation associated with dementia Evaluate patient cases and develop care plans that emphasize patient safety 	 At the completion of this activity, the technician will be able to: Classify common types of dementia Review medications of choice for memory loss and agitation associated with dementia Evaluate patient cases and support patient care plans that emphasize patient safety 		
12:15 pm-1:	12:15 pm-1:30 pm: Lunch (Provided)			


1:30 pm- 2:30 pm	The Value of Integrating Pharmacists into Primary Care Patricia H. Fabel, PharmD, BCPS (1.0 hours, ACPE UAN 0062-0000-20-005-L04-P/T, knowledge-based)		
	 At the completion of this activity, the pharmacist will be able to: 1. Recognize the benefit of incorporating a pharmacist into primary care settings for the management of high blood pressure, high cholesterol and diabetes 2. Describe the economic feasibility of integrating a pharmacist into primary care settings 	 At the completion of this activity, the technician will be able to: Recognize the benefit of incorporating a pharmacist into primary care settings for the management of high blood pressure, high cholesterol and diabetes Describe the economic feasibility of integrating a pharmacist into primary care settings Discuss opportunities for pharmacy technicians to support pharmacy-based services in primary care settings 	
2:35 pm- 4:05 pm	Top 10 Infectious Diseases Topics of 2019 Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS (1.5 hours, ACPE UAN 0062-0000-20-006-L01-P/T, application-based)		
	 At the completion of this activity, the pharmacist will be able to: 1. Apply updated infectious diseases treatment guidelines and policies to antimicrobial recommendations 2. Analyze clinical implications of peer-reviewed infectious diseases literature 3. Determine the role of newly approved antimicrobials 4. Acknowledge emerging pathogens both nationally and globally 5. Discuss changes in roles and responsibilities of pharmacists in managing infectious diseases 	 At the completion of this activity, the technician will be able to: 1. Identify the importance of infectious diseases treatment guidelines and policies 2. Recognize newly approved antimicrobials 3. Identify emerging pathogens both nationally and globally 4. Examine opportunities for pharmacy technicians to impact the management of infectious diseases 	
4:05 pm: Ev	valuation Instructions; Adjourn		

Day 2: Full Program Agenda and Learning Objectives - Saturday, February 2

	8:30 am: Registration/Check-In and Welcome (Light continental breakfast provided)			
8:30 am-	Drugs of Abuse: A Focused Update on Abuse and Monitoring			
9:30 am	Jordan Cooler, PharmD, BCPP (1.0 hours, ACPE UAN 0062-0000-20-007-L01-P/T, application-based)			
	 At the completion of this activity, the pharmacist will be able to: 1. Identify risk factors for inappropriate use of controlled substances and other prescription and non-prescription drugs of abuse 2. Explain best practices for identifying and mitigating drug abuse 	 At the completion of this activity, the technician will be able to: 1. Describe best practices for identifying and mitigating drug abuse and misuse based on available data 		
	and misuse based on available data			
	Apply recommendations in a specific pharmacy practice setting			
	5 am: Break			
9:45 am-	Hypertension: Classification, Management, and M	Ionitoring of the Most Common Disease State		
10:45 am	Julie Sease, PharmD, FCCP (1.0 hours, ACPE U	AN 0062-0000-20-008-L01-P/T, application-based)		
	 At the completion of this activity, the pharmacist will be able to: 1. Use patient case information to categorize a patient as having normal blood pressure, elevated blood pressure, stage 1 hypertension, or stage 2 hypertension and assign an appropriate evidence based blood pressure goal for the patient 2. Recommend an appropriate initial evidence based treatment plan (including nonpharmacologic and pharmacologic therapies) for a patient based on their presenting blood pressure value and patient specific factors (including compelling indications, laboratory evaluation, and ASCVD risk) 3. Justify an appropriate evidence based treatment plan for a patient who is not meeting blood pressure goal on their current regimen 4. Educate a patient who will be conducting home blood pressure monitoring about the guideline-recommended way to complete this 	 At the completion of this activity, the technician will be able to: 1. Identify blood pressure measurements that fall into the following categories: normal blood pressure, elevated blood pressure, stage 1 hypertension, or stage 2 hypertension 2. Name antihypertensive classes that are used as initial treatment in patients with hypertension and state nonpharmacologic recommendations that may be made to help a patient lower their blood pressure 3. Recognize appropriate pharmacotherapeutic modifications that might be made for a patient taking antihypertensive therapy when their initial regimen fails to get them to their blood pressure goal 4. Educate a patient who will be conducting home blood pressure monitoring about the guideline-recommended way to complete this 		
10:50 am-	Determining Decisions and Deciphering D	ilemmas in Dyslipidemia with Updated		
11:50 am	American College of Cardiology/American H	leart Association Cholesterol Guidelines		
	Cynthia Phillips, PharmD, CDE (1.0 hours, ACPE UAN 0062-0000-20-009-L01-P/T, application-based)			
	At the completion of this activity, the pharmacist will be able to: 1. Investigate patient risk of atherosclerotic cardiovascular disease (ASCVD) using risk calculators and risk enhancing factors 2. Analyze updates in the American College of Cardiology (ACC) (American Licent Acceptions)	At the completion of this activity, the technician will be able to: 1. Identify specific indications for statin and non-statin therapies in patients with atherosclerotic cardiovascular disease (ASCVD) 2. Discuss that require phormagint interpretion in		
	 /American Heart Association (AHA) Cholesterol Guidelines 3. Discuss the appropriate use of non-statin therapies in ASCVD prevention 4. Apply updated ACC/AHA Cholesterol Guidelines to patient 	 Discuss issues that require pharmacist intervention in patients with ASCVD Identify potential sources of error with use of statin and non-statin therapies 		
11:50 am-12	cases 2:45 pm: Lunch (Provided)			
11.50 alli*12				

12:45 pm-	Beyond Diabetes: Benefits of SGLT	2 Inhibitors and GLP-1 Agonists		
1:45 pm	Brie Dunn, PharmD (1.0 hours, ACPE UAN 0062-0000-20-010-L01-P/T, application-based)			
	 At the completion of this activity, the pharmacist will be able to: 1. Describe the advantages and disadvantages of SGLT2 inhibitors and GLP-1 agonists 2. Identify potential benefits of SGLT2 inhibitors and GLP-1 agonists based on recent clinical trial data 3. Compare and contrast cardiovascular and renal benefits for available SGLT2 inhibitors and GLP-1 agonists 4. Develop and justify an evidence-based plan for a specific patient in order to provide cardiovascular and/or renal benefit. given a case scenario 	 At the completion of this activity, the technician will be able to: 1. Describe the advantages and disadvantages of SGLT2 inhibitors and GLP-1 agonists 2. Identify potential benefits of SGLT2 inhibitors and GLP-1 agonists based on recent clinical trial data 3. Compare and contrast cardiovascular and renal benefits for available SGLT2 inhibitors and GLP-1 agonists 		
1:45 am-2:0	1:45 am-2:00 pm: Break			
2:00 pm –	Community Acquired	Pneumonia Update		
3:00 pm	Hana Rac Winders, PharmD, BCIDP (1.0 hours, ACPE UAN 0062-0000-20-011-L01-P/T, application-based)			
	 At the completion of this activity, the pharmacist will be able to: 1. Identify the differences between the 2007 and 2019 community-acquired pneumonia (CAP) guidelines 2. Discuss the evidence behind recommendations in the new CAP guidelines 3. Apply the new CAP guidelines to patient cases 4. Recognize the pharmacist's role in antimicrobial stewardship relating to the treatment of CAP 	 At the completion of this activity, the technician will be able to: 1. Identify the differences between the 2007 and 2019 community-acquired pneumonia (CAP) guidelines 2. Discuss the recommendations in the new CAP guidelines 3. Recognize the pharmacy technician's role in antimicrobial stewardship relating to the treatment of CAP 		
3:05 pm –	Management of Pit Viper and E	Black Widow Envenomation		
4:05 pm	Jill Michels, PharmD, DABAT (1.0 hours, ACPE U			
Ø	 At the completion of this activity, the pharmacist will be able to: Discuss treatment myths associated with pit viper envenomation. Recommend supportive treatment for pit viper envenomation. Compare Crotalidae Polyvalent Immune Fab (Ovine) antivenom to Crotalidae Immune F(ab')2 (Equine) antivenom 	 At the completion of this activity, the technician will be able to: 1. Discuss treatment myths associated with pit viper envenomation 2. Compare Crotalidae Polyvalent Immune Fab (Ovine) antivenom to Crotalidae Immune F(ab')2 (Equine) antivenom 		
4:05 pm; 5	4. List treatment options for black widow spider bite	3. Recognize treatment options for black widow spider bite		
4:05 pm: Evaluation Instructions; Adjourn				

Home Study Programming Available to All Registrants



Please contact us at <u>CE@cop.sc.edu</u> or 803-777-9979 with any questions!